Telecoms Today
SEE OTHER BRANDS

Catch up with telecommunications news from the world

Telecoms Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Telecoms Today.

Press releases published on October 8, 2025

AmiViz Partners with Corgea to Strengthen Code Security Across the Middle East
Waypoint 33 Named a U.S. Distributor for Cellular Expert, Bringing Advanced RF and Geospatial Network Planning Solutions
DevX Highlights Steve Morris on Website Security Best Practices: NEWMEDIA.COM Brings Technical Rigor to the Forefront
Rattle Tech and Linear Systems Form Strategic Partnership to Advance Cloud and AI Solutions for Law Enforcement
Nationwide Answering Service Ambs Call Center Honored with 2025 CAM-X Award of Excellence
TierOne to Showcase NaaS CX, Smart NOC, and NaaS NOC Solutions at GITEX 2025
IPQS Launches Enterprise Fintech Solutions & Partnerships
American Marketing Association Launches Digital Credentialing Program to Empower Marketers
Optical Zonu Announces Its Unmanned Aircraft System RFoF Solutions
AVer Debuts VB150 4K Video Bar for Effortless AI Meeting Collaboration
Digital Zone Explores New Partnerships at HITEX 2025
Nilo Therapeutics startet mit einer Serie-A-Finanzierung in Höhe von 101 Mio. USD zur Entwicklung einer neuen Medikamentenklasse, die auf neuronale Schaltkreise bei Immunerkrankungen abzielt, und ernennt Kim Seth zum Chief Executive Officer
Nilo Therapeutics se lanza con un financiamiento Serie A de 101 millones de dólares para avanzar una nueva clase de medicamentos dirigidos a los circuitos neuronales en enfermedades inmunológicas y nombra a Kim Seth como director ejecutivo
Lancement de Nilo Therapeutics avec un financement de série A de 101 millions de dollars en vue de développer une nouvelle classe de médicaments ciblant les circuits neuronaux dans les maladies immunitaires, et nomination de Kim Seth au poste de…
Nilo Therapeutics מושקה עם מימון סדרה A של 101 מיליון דולר לקידום סוג חדש של תרופות המכוונות למעגלים עצביים במחלות חיסוניות וממנה את קים סת' למנכ"ל
ナイロ・セラピューティクス (Nilo Therapeutics)、免疫疾患における神経回路を標的とする新しい種類の医薬品開発を推進するため、1億100万米ドル (約154億1,290万円) のシリーズA資金調達を実施し、キム・セス博士 (Kim Seth, Ph.D.) を最高経営責任者 (CEO) に任…
Nilo Therapeutics diluncurkan dengan pendanaan Seri A senilai 101 juta dolar AS untuk mengembangkan kelas baru obat-obatan yang menargetkan sirkuit saraf pada penyakit imun, serta menunjuk Kim Seth sebagai Direktur Utama
Nilo Therapeutics dilancarkan dengan pembiayaan Siri A sebanyak $101 juta untuk membangunkan kelas baharu ubat-ubatan yang menyasarkan litar neural dalam penyakit imun, serta melantik Kim Seth sebagai Ketua Pegawai Eksekutif
Nilo Therapeutics é lançada com financiamento de US $101 milhões da Série A para promover uma nova classe de medicamentos direcionados a circuitos neurais em doenças imunológicas e nomeia Kim Seth como CEO
니로 테라퓨틱스(Nilo Therapeutics), 면역질환의 신경 회로를 표적으로 하는 신약 계열 개발 추진 목표로 1억 100만 달러 규모의 시리즈 A 투자 유치에 나서며 킴 세스(Kim Seth) 박사를 CEO로 임명

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions